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Pathophysiological basis of laboratory 
parameter changes we monitor in 
dialysis patients
Igor Žabić
Department of Internal Medicine, General Hospital “T. Bardek”, 
Koprivnica, Croatia
Chronic kidney disease is a state where kidney los-
es one of it functions during time, as the results of 
an illness primarily affecting kidneys or any other 
illness which damages kidneys as part of its multi-
organ damage. The stage of renal failure is as-
sessed through creatinine clearance. Several modi-
fied formulas today aim to assess renal function as 
precisely as possible, on individual level, and are 
based on a number of variables. The loss of renal 
function (excretory, metabolic, endocrinological) 
leads to disorders of many organ systems, which is 
first detected through blood and urine laboratory 
tests. Anaemia of chronic disease is developed 
through the reduced production of erythropoietin 
in kidneys, suppressed erythropoiesis due to 
chronic inflammation or even blood loss in the di-
alysis system or frequent blood draws for labora-
tory tests. The excretory kidney function is re-
duced, which changes the dilution of urine, causes 
water retention, electrolyte disorders often ac-
companied by blood acidosis. The reduced excre-
tion of calcium and phosphate as well as the re-
duced vitamin D activation in kidneys (calcitriol), 
leads to enhanced secretion of parathyroid hor-
mone, and then to hyperplasia of parathyroid 
glands and the development of secondary hyper-
parathyroidism with complications such as renal 
osteodystrophy and calcification. The damage and 
the increased permeability of glomerular basal 
membrane for proteins (selective or non-selective) 
often results in the development of severe hypoal-
buminemia, a coagulation disorder occurring after 
the loss of clotting factor as well as failure of medi-
cine and hormone effects directly connected to 
plasma proteins. At the final stage of renal failure 
(creatinine clearance is lower than 15 mL/
min/1.73m²), it is necessary to commence treat-
ment with one of the kidney function replacement 
forms (haemodialysis, peritoneal dialysis or kidney 
transplant). The choice of treatment modality is 
subject to the expertise of a nephrologist, sur-
geon, urologist together with the patient, in order 
to ensure an optimal quality of life. Each method 
has its advantages and possible complications 
that need to be considered. The start of treatment 
of the chronic renal disease with one of the forms 
of kidney function replacement demands a thor-
ough clinical monitoring of the patient’s condi-
tion, the assessment of the dialysis process ade-
quacy and prompt reaction by clinicians, which is 
greatly based on fast, available and reliable labora-
tory test values.
Corresponding author: igor.zabic@gmail.com
Preanalytical and postanalytical 
problems in laboratory analysis of 
haemodialysis patient samples
Tihana Herceg Brlek, Ivanka Ostroški
Medical Biochemistry Laboratory, General Hospital Varaždin, 
Varaždin, Croatia
Accurate, reliable and clinically useful laboratory 
test results for the right patient at the right time is 
one of the goals of laboratory medicine. It is im-
portant to keep in mind that patient outcome can 
be affected by preanalytical errors. Patients with 
end-stage kidney failure are treated with complex 
therapeutic procedures which is why guidelines 
for obtaining analytically adequate sample should 
be followed. Wide variety of sample types can be 
submitted for numerous laboratory testing, such 
as: samples from a central line or peripheral vein, 
dialysate samples, sample drawn before or after 
the dialysis treatments. For right clinical interpre-
tation of a laboratory result, in relation to a refer-
ence group or longitudinally monitored, clinicians 
should know whether the test results were ob-
tained on point of care devices or in core labora-
tory.
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Peritoneal equilibration test (PET) that is per-
formed in peritoneal dialysis patients requires sev-
eral laboratory measurements in dialysate sam-
ples. Proper specimen labelling and type of units 
of measurement is needed for the right interpreta-
tion of the PET. Measurements such as complete 
blood count, parathyroid hormone, potassium, 
phosphorus, calcium balance determination, 
blood gas analysis, serum protein electrophoresis 
or the concentration of immunosuppressive drugs 
have their own characteristics. Continuous educa-
tion and cooperation are very important for all 
health professionals that participate in the process 
from ordering to interpretation of the test results.
Corresponding author: tihana.herceg-brlek@obv.hr
Mineral metabolism monitoring 
in haemodialysis patients with 
secondary hyperparathyroidism
Alen Andrović
Department of Internal Medicine, General Hospital Varaždin, 
Varaždin, Croatia
Chronic kidney disease (CKD) is a global public 
health problem affecting 5-10% of the world pop-
ulation. Disorders of bone and mineral metabo-
lism are common complications of dialysis patients 
that can manifested as one or more abnormalities 
in laboratory parameters (calcium, phosphorous, 
parathyroid hormone (PTH), and vitamin D), vol-
ume, growth and structural bone changes and 
pathological calcifications. The pathophysiology 
of chronic kidney disease-mineral and bone disor-
der (CKD-MBD) is very complex and involves a 
number of feedback loops between the kidney, 
bone, intestine and the vasculature. The main hor-
mones and factors that contribute to the kidney 
regulation of phosphorus and calcium include 
PTH, fibroblast growth factor 23 (FGF-23), klotho 
and 1,25-dihydroxyvitamin D (1,25(OH)2D). Sec-
ondary hyperparathyroidism develops as a conse-
quence of mineral metabolism disturbances and is 
characterized by elevated serum PTH and parathy-
roid hyperplasia. To help clinicians recognize ab-
normalities in mineral metabolism markers target 
ranges have been defined for serum PTH, calcium 
and phosphorus concentrations in clinical practice 
guidelines. Recommended frequencies for mineral 
metabolism monitoring in haemodialysis patients 
also vary between guidelines with no firm consen-
sus on optimum frequency. In Japan, biweekly or 
monthly measurement is recommended for calci-
um/phosphorus, which is more frequent than val-
ues defined in the KDOQI (Kidney Disease Out-
comes Quality Initiative) or KDIGO (Kidney Disease 
Improvement of Global Outcomes) guidelines. Re-
garding PTH trimonthly measurement is recom-
mended in Japan whereas less frequent measure-
ment (every 3-6 months) is recommended in the 
KDIGO guideline. Early detection, optimal treat-
ment and regular monitoring CKD-MBD in accord-
ance with current guidelines can reduce the all-
cause and cardiovascular mortality in haemodialy-
sis patients.
Corresponding author: aandrovic19@gmail.com
Haematological parameters in 
samples of dialysis patients
Irena Kocijan
Medical Biochemistry Laboratory, General Hospital Varaždin, 
Varaždin, Croatia
Haemodialysed patients have an increased risk of 
developing haematological disorders due to the 
nature of underlying disease as well as the thera-
peutic procedures themselves. In addition to 
thrombocytopenia and platelet dysfunction, the 
most common disorder is anaemia. Etiological 
background is multifactorial, primarily caused by 
the long-term endocrinological, mechanical, meta-
bolic, toxic and nutritional issues. Inadequate 
erythropoietin synthesis, hyperparathyroidism, 
blood loss during venipuncture or dialysis might 
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develop, besides membrane and intracellular 
erythrocyte changes,  reduced availability of iron, 
folate and other nutrients. According to Kidney Dis-
ease Improvement of Global Outcomes guideline 
(KDIGO) for diagnosis and evaluation of anaemia in 
chronic kidney disease, as well as for monitoring 
therapeutic procedures, a complete blood count, 
reticulocytes, ferritin, transferrin saturation, vita-
min B12 and folate measuring are recommended. 
However, due to the complex and interdependent 
pathophysiological mechanisms, including volem-
ic and cardiovascular disorders, inflammatory reac-
tion, immune dysregulation, disturbed erythro-
poiesis and the influence of therapeutic protocol, 
these standard markers in samples of dialysis pa-
tients are changed and may be unreliable indica-
tors of their erythroid status. More informative and 
diagnostically accurate indices are still needed to 
help clinicians in adjusting therapy as well as main-
taining haemoglobin within the recommended 
limits. Although erythrocytes are primarily used in 
clinical practice, reticulocyte parameters more di-
rectly reflect changes in the hemoglobinization of 
erythron and can provide the fastest information 
about the functional iron availability in patients re-
ceiving erythropoietin.
Corresponding author: ikocija9@gmail.com
Are laboratory biomarkers of 
cardiovascular changes in dialysis 
patients sufficiently informative?
Sonja Podolar, Ana Matiša
Medical Biochemistry Laboratory, General Hospital „Dr.Tomislav 
Bardek“, Koprivnica, Croatia
Cardiovascular disease (CVD) is the leading cause 
of morbidity and mortality in patients with chronic 
kidney disease (CKD). Numerous studies have 
found a strong association between decrease of 
glomerular filtration rate as a marker of renal dis-
ease progression and increasing prevalence of 
clinical manifestations of CVD. In patients with 
CKD, especially patients with end-stage renal dis-
ease and patients on dialysis, besides traditional 
risk factors for the development of CVD, such as 
diabetes, hypertension, high cholesterol, obesity 
etc., there could be found additional uremic-relat-
ed factors such as anaemia, inflammation, oxida-
tive stress and lipid and mineral metabolism disor-
ders. An additional challenge for early diagnosis 
and managing CVD in CKD patients is the interpre-
tation of reno-cardiovascular biomarkers. Com-
monly used biomarkers are brain natriuretic pep-
tides (BNP/NT-proBNP), as biomarkers of heart fail-
ure, and high-sensitivity troponins (hsTnI), as mark-
ers of ischemic myocardial damage. The blood val-
ues of these biomarkers in patients with CKD, 
compared to the cut-off values obtained for the 
general population, are often elevated even when 
there are no clear clinical signs of cardiovascular 
changes. This increase is probably associated with 
two mechanism: decreased clearance of biomark-
ers due to decreased renal function, and renal dis-
ease-related pathophysiological mechanisms that 
also lead to damage of the heart muscle. In addi-
tion, in haemodialysis patients, the type of dialysis 
itself or the materials of dialytic membrane may 
affect biomarker blood concentrations. Because of 
all this, in CKD patients for both, BNP/NT-pro BNP 
and hsTn, the cut-off values should be set higher 
than in the general population. On the other hand, 
by raising the cut-off values diagnostic accuracy 
decreases and a single determination of blood 
concentration for CVD diagnosis is not recom-
mended. Serial estimation for the basal blood val-
ue of natriuretic peptides might provide more use-
ful information. Similar, only serial determination 
of hsTn and dynamic changes of more than 20% 
should be used in diagnosing acute coronary syn-
drome. For early recognition of CVD in CKD pa-
tients, as multi-organ pathophysiological mecha-
nisms are involved, multi-biomarker estimation 
could be beneficial.
Corresponding author: sopodolar@obkoprivnica.hr
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Nutritional status monitoring of 
patients undergoing chronic dialysis
Valentina Kutnjak Flac
Medical Biochemistry Laboratory, County Hospital Čakovec, 
Čakovec, Croatia
Patients with chronic kidney disease (CKD), espe-
cially those with end-stage renal disease who are 
undergoing chronic haemodialysis, are at high risk 
for developing protein-energy malnutrition (PEM). 
Protein-energy malnutrition is a complex clinical 
condition characterized by a progressive decrease 
in protein reserves and disturbance of energy bal-
ance leading to increased hospitalization and 
death rates. 
During the renal function deterioration and devel-
opment of uremic syndrome, there is a conform-
ing decline of nutritional status partly due to loss 
of appetite, various comorbidities affecting diges-
tive function, depression, socioeconomic situa-
tion, patient isolation, and mostly because of loss 
of nutrients during dialysis (amino acids, peptides, 
proteins, glucose, water-soluble vitamins, and oth-
er bioactive compounds). Therefore, the early di-
agnosis of PEM justifies regular and vigilant moni-
toring of nutritional status. 
Several indicators are available to assess the nutri-
tional status of renal patients, which are used in-
dependently or jointly as part of a systematic eval-
uation. It is recommended to use several different 
methods simultaneously to achieve a comprehen-
sive assessment of nutritional status by examining 
different parameters. The National Kidney Foun-
dation (USA) has developed guidelines which pro-
pose that patients on chronic haemodialysis 
should be routinely assessed for nutritional status 
by a panel of tests at certain time intervals. The 
proposed panel of complementary tests includes 
pre-dialysis serum albumin, percent of usual body 
weight, percent of standard bodyweight, subjec-
tive global assessment (SGA), dietary interviews 
and diaries, and nPNA (normalized Protein Equiva-
lent of Total Nitrogen Appearance). 
Serum albumin is currently most common param-
eter used for screening patients at high-risk of de-
veloping PEM. For assessment of nutrition several 
other biochemical parameters such as: serum pre-
albumin, transferrin, serum creatinine and total 
cholesterol can be used.
Corresponding author: valentina.kutnjak@gmail.com
